Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced that on November 4, 2025 it granted 77,650 restricted stock units (RSUs) to 23 new employees under its 2017 Inducement Equity Incentive Plan pursuant to NASDAQ Rule 5635(c)(4).

The RSUs vest 25% on the one-year anniversary of each recipient’s vesting commencement date and the remaining 75% in twelve equal quarterly installments thereafter, subject to continued employment. The awards are governed by the 2017 Inducement Equity Incentive Plan and individual RSU agreements.

Esperion is a commercial-stage biopharmaceutical company commercializing FDA-approved oral, once-daily non-statin medicines for patients with elevated LDL-C and references the nearly 14,000-patient CLEAR Cardiovascular Outcomes Trial.

ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.

The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient’s vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion’s 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information: 
Investors:  
Alina Venezia 
investorrelations@esperion.com
(734) 887-3903 

Media:  
Tiffany Aldrich  
corporateteam@esperion.com
(616) 443-8438 

FAQ

What did Esperion (ESPR) announce on November 4, 2025 about employee equity?

Esperion granted 77,650 RSUs to 23 new employees under its 2017 Inducement Equity Incentive Plan on November 4, 2025.

How do the RSU vesting terms for ESPR inducement grants work?

Each RSU vests 25% at the one-year anniversary of the vesting start date and the remaining 75% in 12 equal quarterly installments, subject to continued employment.

Under which plan were Esperion's November 2025 inducement RSUs awarded?

The awards were made under Esperion’s 2017 Inducement Equity Incentive Plan pursuant to NASDAQ Rule 5635(c)(4).

Does the November 2025 RSU announcement state the impact on ESPR share count or dilution?

No specific share count impact or dilution percentage was provided in the announcement.

What product and trial does Esperion highlight in the announcement?

Esperion highlights its FDA-approved oral, once-daily non-statin medicines and the nearly 14,000-patient CLEAR Cardiovascular Outcomes Trial.

Who can investors contact for more information about the ESPR inducement grants?

Investors can contact Alina Venezia at investorrelations@esperion.com or (734) 887-3903 as listed in the announcement.